DOCSLIB.ORG

EIPICO General Product List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EIPICO General Product List EIPICO General Product List S.N Product Name Inqredients 1.Analgesics, Antipyretics ,Antiinflammatories & AntirheumaticsDescription 1.1.Analgesics Antipyretics 1 CETAL Cold & Flu Caplet Paracetamol 500mg + Pseudoephdrine Hcl 30mg + Chlorpheniramine maleate 2mg. 2 Cetal Oral Drops Paracetamol 10% 3 Cetal Sinus Tab Paracetamol 500mg + Pseudoephdrine Hcl30mg 4 Cetal Extra Paracetamol D.C 500 mg + Caffiene anhydrous 65 mg 5 Cetal Supp 120 mg Paracetamol 120mg / supp. 6 Cetal Rectal Supp* 300 mg Paracetamol 300/Supp 7 Cetal Suspension Paracetamol 5% 8 Cetal Syrup Paracetamol 2.4% 9 Cetal Tab Paracetamol 500mg /tab. Pseudoephedrine HCl 30 mg 10 Conta-flu tablets +Chlorpheniramine maleate 3 mg 1.2.Analgesics ,Antiinflammatories & Antirheumatics 11 Epifenac 12.5 mg Rectal suppositories Diclofenac sodium 12.5 mg/supp. 12 Epifenac 25 mg Enteric coated tablets Diclofenac sodium 25 mg / ECT 13 Epifenac 25 mg Rectal suppositories Diclofenac sodium 25 mg/supp. 14 Epifenac 50 mg Enteric coated tablets Diclofenac sodium 50 mg/ ECT 15 Epifenac 50 mg Rectal suppositories Diclofenac sodium Micronised 50mg/Supp 16 Epifenac 75 mg Sustained Release sugar coated Tablets (T) Diclofenac sodium Micronised 75 mg/ SR SCT 17 Epifenac 100 mg Rectal suppositories Diclofenac sodium 100 mg/supp. 18 Epifenac 100 mg Sustained Release sugar coated Tablets (T) Diclofenac sodium Micronised 100 mg/SR SCT 19 Epifenac ampoule for IM injection or IV infusion Diclofenac sodium 75 mg / 3 ml 20 Epicotil 20 mg film coated tablets Tenoxicam 20 mg /FCT 21 Epicotil 20 mg suppository Tenoxicam 20 mg /supp. 22 Epicotil 20 mg vial Tenoxicam 20 mg / vial 23 Kevice Hard Gelatin Capsules (T)* Ketoprofen 50 mg 24 Kevice Rectal Suppository (T)* Ketoprofen 100 mg Each 1 ml contains: 25 Kevice Solution for I.M injection (T)* Ketoprofen 50 mg 26 Mafo 200 mg Film Coated Tablets (T) Ibuprofen 200 mg / tablet 27 Mafo 400 mg Film Coated Tablets (T) Ibuprofen 400 mg / tablet 28 Mafo Syrup (T) Ibuprofen 100 mg / 5ml 29 Nefopam Solution for IM & slow IV injection in Ampoule Nefopam Hydrochloride 20 mg / 1 ml 30 Vastaflam Sugar coated tablets 50 mg Diclofenac potassium 50 mg 1.3.Muscle Relaxants 31 Epicoflex Tablets Orphenadrine Citrate 100 mg / Tablet Orphenadrine Citrate 35mg + 32 Epigesic Tablets Paracetamol D.C 500 mg 2.Gout Treatments 33 No-uric 100 mg tablets Allopurinol 100 mg 34 No-uric 300 mg tablets Allopurinol 300 mg 3.Antibiotics and other Anti-infective drugs 3.1.Penicillins and Penicillin Combinations 35 Epicocillin 500 mg CAP. Ampicillin 500mg 36 Epicocillin 250 mg Vial Ampicillin(as sodium) 250mg/vial 37 Epicocillin 0.5 g VIAL Ampicillin 500mg 38 Epicocillin l.0 g VIAL Ampicillin lg 39 E-MOX 250 mg DRY MIX (Powder for oral Suspension) Amoxicillin 250mg/5ml. 40 E-MOX 500 mg CAP. Amoxycillin 500mg 41 E-MOX 0.5 g VIAL Amoxicillin (as Amoxicllin sodium) 500 mg/ vial 42 E-MOX l.0 g VIAL Amoxicillin (as sodium) 1.0 g / vial 43 E-Moxclav 156 mg powder for oral suspension Amoxycillin 125mg + Clavulanicacid 31.25 mg 44 E-Moxclav 312.5 mg powder for oral suspension Amoxycillin 250mg + Clavulanic acid 62.5mg 45 E-Moxclav 228.5 mg powder for oral suspension Amoxycillin 200mg + Clavulanic acid 28.5 mg 46 E-Moxclav 457 mg powder for oral suspension Amoxycillin 400mg + Clavulanic acid 57.5mg 47 E-Moxclav 642.6 mg powder for oral suspension* Amoxycillin 600mg + Clavulanic acid 42.6 mg 48 E-Moxclav 375 mg TAB. Amoxycillin 250mg + Clavulanic acid 125mg 49 E-Moxclav 625 mg TAB. Amoxycillin 500mg + Clavulanicacid 125mg 50 E-Moxclav 1.0 g TAB. Amoxycillin 875mg + Clavulanic acid 125mg Flucloxacillin 125 mg/5ml 51 Flumox 250mg Dry Mix. & Amoxycillin 125 mg/5ml Flucloxcalin 125 mg 52 Flumox 250mg Hard Gelatin Capsules & Amoxycillin 125 mg Amoxycillin 250 mg 53 Flumox 500mg Hard Gelatin Capsules +Flucloxacillin 250 mg Flucloxacillin 500 mg 54 Flumox 1000 mg Film Coated Tablets & Amoxycillin 500 mg / tablet 55 Flumox 0.5 mg Vial Flucloxacillin (as sodium salt ) 250 mg & Amoxycillin(as sodium salt ) 250 mg 56 Flumox 1.0 g Vial Flucloxacillin (as sodium salt) 500 mg & Amoxycillin(as sodium salt ) 500mg 3.2. Cephalosporins 57 Cefidime 1.0 g Powder in Vials Ceftazidime 1000 mg Cefidime 2.0 g Powder for solution for IV injection or Infusion in 58 Ceftazidime 2 gm vials 59 Cefidime 0.25 g powder for solution for I.M/I.V Injection Ceftazidime 250 mg 60 Cefidime 0.5 g Vials of powder for deep I.M. / I.V. Injection Ceftazidime 500 mg 61 Cefotax 1.0 g Powder in vial for I.M, I.V injection & IV infusion Cefotaxime 1000 mg 62 Cefotax 2.0 g Powder in vial for I.M, I.V injection & IV infusion Cefotaxime 2.0 g 63 Cefotax 0.25 g Powder in vial for IM/IV injection Cefotaxime 250mg Cefotax 0.5 g powder for solution in vial for IM injection, IV 64 Cefotaxime 500mg injection or infusion 65 Cefozon 0.5 g powder in vials for I.M/I.V injection Cefoperazone 500 mg 66 Cefozon 1 g powder in vials for I.M & I.V injection & Infusion Cefoperazone 1 g 67 Cefozon 2 g powder in vials for I.M & I.V injection & Infusion Cefoperazone 2 g 68 Cephradine 0.5 g Powder in Vial for solution for IM, IV inj Cephradine 500 mg 69 Cephradine 1.0 g Powder in Vial for solution for IM, IV inj Cephradine 1 g 70 Cefidime 0.25 gm vial I.M., I.V. Ceftazidime 250 mg 71 Cefidime 0.5 gm vial I.M., I.V. Ceftazidime 500 mg 72 Cefidime l.0 gm vial I.M., I.V. Ceftazidime 1 g 73 Cefidime 2.0 gm vial I.M., I.V. Ceftazidime 2 g 74 Epicephin 0.25 g vials I.M. (T) Ceftriaxone 250 mg 75 Epicephin 0.5 g VIAL I.M. Ceftriaxone 500 mg 76 Epicephin 0.5 g VIAL I.V. Ceftriaxone 500 mg 77 Epicephin l.0 g VIAL I.M. Ceftriaxone 1 g 78 Epicephin l.0 g powder for solution for slow I.V. Injection & I.V. InfusionCeftriaxone 1 g 1Vial+1 Solvent 79 Epicephin 2.0 g powder for solution for slow I.V. Injection & I.V. InfusionCeftriaxone 2 g 1Vial+1 Solvent 80 Novactam 375 mg tab Sultamicilin eqv. 375 ampicillin/sulbactam Novactam 500/250 mg Powder for solution for IM / IV Injection or Ampicillin 500 mg) 81 IV infusion + Sulbactam 250 mg Ampicillin 1000 mg 82 Novactam 1000/500 mg Powder for solution for IM / IV Injection + Sulbactam 500 mg 3.3. Amino Glycosides 83 Amikacin 100 mg VIAL Amikacin sulphate 100 mg 84 Amikacin 500 mg VIAL Amikacin sulphate 500 mg 85 Doxydox 100mg CAP. Doxycycline 100 mg / Capsule Epigent 20 mg / 2 ml solution for IM, slow IV inj or infusion in Each ampoule of 2 ml contains: 86 Ampoules Gentamycin (as sulphate) 20 mg Each ampoule of 1 ml contains: 87 Epigent 40 mg / 1 ml IM/IV Ampoules* Gentamycin (as sulphate) 80 mg Each ampoule of 2 ml contains: 88 Epigent 40 mg / 2 ml IM/IV Ampoules Gentamycin Sulphate 63 mg Each ampoule of 2 ml contains: 89 Epigent 80 mg / 2 ml Ampoules Gentamycin (as sulphate) 80 mg 3.4.Quinolone derivatives 90 Ciprocin 250mg TAB. Ciprofloxacin 250mg 91 Ciprocin 500mg TAB. Ciprofloxacin 500mg 92 Ciprocin 750mg TAB. Ciprofloxacin 750mg 93 Ciprocin Vials for IV infusion Ciprocin 200 mg 93 Ciprocin Vials for IV infusion Ciprocin 400 mg 94 Epicoflocin 200mg TAB. Ofloxacin 200 mg 95 Epinor 400 mg Film Coated Tablets Norfloxacin 400 mg / Film Coated Tablet 3.5. Macrolides derivatives Each 5 ml (after reconstitution) contains: 96 Epizithro powder for oral suspension Azithromycin 200 mg 97 Epizithro Hard Gelatin Capsules (T)* Azithromycin 500 mg 3.6. Sulphonamides & Trimethoprim Each 5 ml contains: 98 Epitrim Oral Suspension Trimethoprim micronized 40 mg 3.7. Antifungal Drugs Each 1 ml susp. Contains: 99 Nystatin Oral Suspension Nystatin 100,000 I.U. 100 Treflucan 150mg CAP. Fluconazole 150mg/cap. 3.8. Antivirals Favipiravir micronized 101 Epifluver Film Coated Tablets 200 mg 102 Episovir 400 mg Film Coated Tablets Sofosbuvir Micronized 400 mg / Film Coated Tablet 103 Epimiraflu Hard Gelatin Capsules Oseltamivir 75 mg/ Capsule 104 Dacladazin 60 mg Film Coated Tablets Daclatasvir 60 mg Remaist 100 mg Lyophilized powder for concentrate for solution for 105 Remdesivir 100 mg I.V Infusion 106 Remaist 5 mg-ml concentrate for solution for I.V Infusion Remdesivir 100mg/20ml Vial 107 Vudinine Film Coated Tablets 100 mg Lamivudine 100 mg 4.Anthelmintics and Schistosomicides 108 Alzental Suspension Albendazole 400mg / 20 ml bottle 109 Alzental Tab Albendazole 200mg / tab. 110 Epiquantel Tab Praziquantel 600 mg / Film Coated Tablet 111 Permax Suspension Mebendazole 100 mg /5 ml 5.Orodentals 112 Tantum-Verde Mouth Wash & Gargle Benzydamine HCl 0.15 g /100ml 113 Tantum verde-p-lozenges Benzydamine HCl 3 mg 6.Gastrointestinal Drugs 6.1.Antacids 114 Epicogel Suspension Dried aluminium hydroxide gel + Magnesium hydroxide + and Dimethicone Dried aluminum hydroxide gel 8.1% & 115 Mucogel Suspension Magnesium hydroxide gel 2.0% 6.2.Ulcer Healing Drugs 6.2.1.Protectants 116 Gastrofait 0.5 g tablets Sucralfate 0.5 g / tablet. 117 Gastrofait 1 g tablets Sucralfate 1.0 g / tablet. 6.2.2. H2 Blockers 118 Cimetidine 200 mg AMP. Cimetidine 200 mg / 2 ml amp. Each ampoule of 2 ml: 119 Epirant 50 mg / 2 ml Ampoules Ranitidine 50 mg Ranitidine HCl 67.4 mg 120 Epirant 150 mg Film Coated Tablets Eq. to Ranitidine 150 mg / Film Coated Tablet 6.2.3.Proton Pump Inhibitors Epirazole Hard Gelatin Capsules 121 Omeprazole 20mg / cap.
Load more

Recommended publications
  • Liquid Chromatography Tandem Mass Spectrometry Determination Of
    The Pharma Innovation Journal 2018; 7(7): 57-61 ISSN (E): 2277- 7695 ISSN (P): 2349-8242 NAAS Rating: 5.03 Liquid chromatography tandem mass spectrometry TPI 2018; 7(7): 57-61 © 2018 TPI determination of prohibited diuretics and other acidic www.thepharmajournal.com Received: 01-05-2018 drugs in human urine: A Review Accepted: 05-06-2018 Anchal Sharma Anchal Sharma, Dr. Rajiv Tonk and Dr. Vivek Sharma M. Pharm Scholar, Delhi Pharmaceutical Sciences and Research University, New Delhi, Abstract India This paper reviews liquid chromatographic-mass spectrometric (LC-MS) procedures for the screening, identification and quantification of doping agents in urine and other biological samples and devoted to Dr. Rajiv Tonk drug testing in sports. Reviewed methods published approximately within the last five years and cited in Associate Professor, Delhi the PubMed database have been divided into groups using the same classification of the 2004 World Pharmaceutical Sciences and Anti-Doping Agency (WADA) Prohibited List. Together with procedures specifically developed for anti- Research University, New Delhi doping analysis, I.C-MS applications used in other fields (e.g., therapeutic drug monitoring, clinical and India forensic toxicology, and detection of drugs illicitly used in livestock production) have been included when considered as potentially extensible to doping control. Information on the reasons or potential Dr. Vivek Sharma abuse by athletes, on the requirements established by WADA for analysis, and on the WADA rules for Assistant Professor, Govt College of Pharmacy Rohru, Himachal the interpretation of analytical finding. The basis of human sports doping control is set by the World Pradesh.
    [Show full text]
  • Extracts from PRAC Recommendations on Signals Adopted at the 9-12 March 2020 PRAC
    6 April 20201 EMA/PRAC/111218/2020 Corr2,3 Pharmacovigilance Risk Assessment Committee (PRAC) New product information wording – Extracts from PRAC recommendations on signals Adopted at the 9-12 March 2020 PRAC The product information wording in this document is extracted from the document entitled ‘PRAC recommendations on signals’ which contains the whole text of the PRAC recommendations for product information update, as well as some general guidance on the handling of signals. It can be found here (in English only). New text to be added to the product information is underlined. Current text to be deleted is struck through. 1. Immune check point inhibitors: atezolizumab; cemiplimab; durvalumab – Tuberculosis (EPITT no 19464) IMFINZI (durvalumab) Summary of product characteristics 4.4. Special warnings and precautions for use Immune-mediated pneumonitis [..] Patients with sSuspected pneumonitis should be evaluated confirmed with radiographic imaging and other infectious and disease-related aetiologies excluded, and managed as recommended in section 4.2. LIBTAYO (cemiplimab) Summary of product characteristics 1 Expected publication date. The actual publication date can be checked on the webpage dedicated to PRAC recommendations on safety signals. 2 A footnote was deleted on 8 April 2020 for the signal on thiazide and thiazide-like diuretics (see page 3). 3 A minor edit was implemented in the product information of the signal on thiazide and thiazide-like diuretics on 5 June 2020 (see page 4). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • Isocratic HPLC Method for Simultaneous Determination of Amlodipine and Xipamide in Human Plasma
    vv ISSN: 2689-7628 DOI: https://dx.doi.org/10.17352/ojabc CHEMISTRY GROUP Received: 06 April, 2020 Research Article Accepted: 05 May, 2020 Published: 06 May, 2020 *Corresponding author: Mahmoud M Sebaiy, Isocratic HPLC Method for Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt, Tel: 01062780060; Fаx: 0552303266; Simultaneous Determination E-mail: Keywords: HPLC; Amlodipine; Xipamide; Human of Amlodipine and Xipamide in plasma; Pharmacokinetic https://www.peertechz.com Human Plasma Mahmoud M Sebaiy1*, Hisham E Abdellatef2, Mohamed A Elmosallamy3 and Mustafa Kh Alshuwaili3,4 1Department of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt 2Department of Analytical Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt 3Department of Chemistry, Faculty of Science, Zagazig University, Zagazig, Egypt 4Ministry of Education, Iraq Abstract An HPLC method had been developed and validated for rapid simultaneous separation and determination of the two antihypertensive drugs, amlodipine and xipamide in human plasma within 5 minutes. Drugs are extracted from plasma using methanol, the environmentally benign solvent, for protein precipitation technique. Separation ® was carried out on a Thermo Scientifi c BDS Hypersil C8 column (5μm, 2.50x4.60 mm) using a mobile phase of methanol: 0.025M KH2PO4 (70: 30, v/v) adjusted to pH 3.49 with ortho - phosphoric acid at ambient temperature. The fl ow rate was 1 ml/min and maximum absorption was measured using DAD detector at 235nm. The retention times of amlodipine and xipamide were recorded to be 4.51 and 3.38 minutes, respectively, indicating a shorter analysis time. Limits of detection were reported to be 0.17 and 0.25 μg/ml for amlodipine and xipamide, respectively, showing a high degree of the method sensitivity.
    [Show full text]
  • Azosemide Is More Potent Than Bumetanide and Various Other Loop
    www.nature.com/scientificreports OPEN Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium- Received: 21 November 2017 Accepted: 14 June 2018 potassium-chloride-cotransporter Published: xx xx xxxx human variants hNKCC1A and hNKCC1B Philip Hampel 1,2, Kerstin Römermann1, Nanna MacAulay 3 & Wolfgang Löscher1,2 The Na+–K+–2Cl− cotransporter NKCC1 plays a role in neuronal Cl− homeostasis secretion and represents a target for brain pathologies with altered NKCC1 function. Two main variants of NKCC1 have been identifed: a full-length NKCC1 transcript (NKCC1A) and a shorter splice variant (NKCC1B) that is particularly enriched in the brain. The loop diuretic bumetanide is often used to inhibit NKCC1 in brain disorders, but only poorly crosses the blood-brain barrier. We determined the sensitivity of the two human NKCC1 splice variants to bumetanide and various other chemically diverse loop diuretics, using the Xenopus oocyte heterologous expression system. Azosemide was the most potent NKCC1 inhibitor (IC50s 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B), being about 4-times more potent than bumetanide. Structurally, a carboxylic group as in bumetanide was not a prerequisite for potent NKCC1 inhibition, whereas loop diuretics without a sulfonamide group were less potent. None of the drugs tested were selective for hNKCC1B vs. hNKCC1A, indicating that loop diuretics are not a useful starting point to design NKCC1B-specifc compounds. Azosemide was found to exert an unexpectedly potent inhibitory efect and as a non-acidic compound, it is more likely to cross the blood-brain barrier than bumetanide. Te Na+–K+–2Cl− cotransporter NKCC1 (encoded by SLC12A2) plays an important role in Cl- uptake in neu- rons both in developing brain and in adult sensory neurons1,2.
    [Show full text]
  • Presented By: Dr. Joohee Pradhan Assistant Professor Department of Pharmaceutical Sciences, MLSU, Udaipur
    Presented By: Dr. Joohee Pradhan Assistant Professor Department of Pharmaceutical Sciences, MLSU, Udaipur OUTLINE • Introduction and Definition • Relevant Physiology of Urine Formation • Classification: different ways • Carbonic anhydrase inhibitors: Acetazolamide*, Methazolamide, Dichlorphenamide. • Thiazides: Chlorthiazide*, Hydrochlorothiazide, Hydroflumethiazide, Cyclothiazide, • Loop diuretics: Furosemide*, Bumetanide, Ethacrynic acid. • Potassium sparing Diuretics: Spironolactone, Triamterene, Amiloride. • Osmotic Diuretics: Mannitol 2 Introduction and Definition • Diuretics (natriuretics) are drugs which cause a net loss of Na+ and water in urine and hence increase the urine output (or) urine volume. • The primary action of most diuretics is the direct inhibition of Na+ reabsorption (increased excretion) at one or more of the four major sites along the nephron. • An increased Na+ excretion is accompanied by anion like Cl- Since NaCl is the major determinant of extracellular fluid volume; Diuretics reduce extracellular fluid volume (decrease in oedema) by decreasing total body NaCl content. 3 Introduction and Definition • Diuretics are very effective in the treatment of conditions like: o chronic heart failure o nephrotic syndrome o chronic hepatic diseases o hypertension o Pregnancy associated oedema o Cirrhosis of the liver. 4 Relevant Physiology of Urine Formation • Kidneys are the organs responsible for urine formation. Two important functions of the kidney are: o To maintain a homeostatis balance of electrolytes and water. o To excrete water soluble end products of metabolites. • Each kidney contains approximately one million nephrons and is capable of forming urine independently. • Urine formation starts from glomerular filtration (g.f.) in a prodigal way. • Normally, about 180 L of fluid is filtered everyday: all soluble constituents of blood minus the plasma proteins (along with substances bound to them) and lipids, are filtered at the glomerulus.
    [Show full text]
  • Evidence Review G: Step 4 Treatment
    National Institute for Health and Care Excellence Final Hypertension in adults: diagnosis and management [G] Evidence review for step 4 treatment NICE guideline NG136 Intervention evidence review underpinning recommendations 1.4.44 to 1.4.50 in the guideline August 2019 Final This evidence review was developed by the National Guideline Centre Hypertension in adults: Final Contents Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian. Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties. NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Sulfa Allergy: Cross-Reactivity Versus Multiple Concurrent Allergies
    American Journal of Infectious Diseases 9 (4): 148-154, 2013 ISSN: 1553-6203 ©2013 Science Publication doi:10.3844/ajidsp.2013.148.154 Published Online 9 (4) 2013 (http://www.thescipub.com/ajid.toc) Sulfa Allergy: Cross-Reactivity Versus Multiple Concurrent Allergies 1Muhammad Tariq Shakoor, 2Samia Ayub and 3Zunaira Ayub 1Resident Physician, Internal Medicine Department, St Mary Mercy Hospital, Livonia, MI, USA 2Resident Physicain, Internal Medicine Department, Mount Auburn Hospital, Cambridge, MA, USA 3Medical Student, Fatima Jinnah Medical College, Lahore, Pakistan Received 2012-10-13, Revised 2013-05-01; Accepted 2013-12-02 ABSTRACT As a medical resident we have always been taught that there is some sort of cross reactivity between sulfonamide antibiotics and nonantibiotic sulfonamides. Even the manufacturer’s package inserts contain a precautionary statement about possible Cross-reactivity. The most common approach to this problem is avoidance of all sulfa containing drugs. However, there are few data supporting this contraindication. Thus we may be withholding appropriate therapies from patients unnecessarily. To provide a critical and comprehensive review of literature to explore either cross reactivity between sulfonamide antibiotics and nonantibiotic sulfonamides is a fact or fiction and to present an approach to use nonantibiotic sulfonamides in sulfa allergic patients. A PubMed and general medline search was conducted using the individual names of nonantibiotic sulfonamides. We reviewed all of the available case reports and studies regarding sulfonamide antibiotic cross-reactivity with nonantibiotic sulfonamides. Also reviewed the manufacturer’s package insert for each nonantibiotic sulfonamide drug for information concerning possible cross-reactivity with sulfonamide antibiotics. Sulfa drug allergy is one word holding the whole cross-reactivity theory in it.
    [Show full text]
  • Review of Existing Classification Efforts
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.1.1 Review of existing classification efforts Due date of deliverable: (15.01.2008) Actual submission date: (07.02.2008) Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UGent Revision 1.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) Task 4.1 : Review of existing classification efforts Authors: Kristof Pil, Elke Raes, Thomas Van den Neste, An-Sofie Goessaert, Jolien Veramme, Alain Verstraete (Ghent University, Belgium) Partners: - F. Javier Alvarez (work package leader), M. Trinidad Gómez-Talegón, Inmaculada Fierro (University of Valladolid, Spain) - Monica Colas, Juan Carlos Gonzalez-Luque (DGT, Spain) - Han de Gier, Sylvia Hummel, Sholeh Mobaser (University of Groningen, the Netherlands) - Martina Albrecht, Michael Heiβing (Bundesanstalt für Straßenwesen, Germany) - Michel Mallaret, Charles Mercier-Guyon (University of Grenoble, Centre Regional de Pharmacovigilance, France) - Vassilis Papakostopoulos, Villy Portouli, Andriani Mousadakou (Centre for Research and Technology Hellas, Greece) DRUID 6th Framework Programme Deliverable D.4.1.1. Revision 1.0 Review of Existing Classification Efforts Page 2 of 127 Introduction DRUID work package 4 focusses on the classification and labeling of medicinal drugs according to their influence on driving performance.
    [Show full text]
  • High Performance Liquid Chromatography for Simultaneous Determination of Xipamide, Triamterene and Hydrochlorothiazide in Bulk Drug Samples and Dosage Forms
    Acta Pharm. 66 (2016) 109–118 Original research paper DOI: 10.1515/acph-2016-0022 High performance liquid chromatography for simultaneous determination of xipamide, triamterene and hydrochlorothiazide in bulk drug samples and dosage forms SOAD S. ABD EL-HAY1, 2 A novel, simple and robust high-performance liquid chro- 2, 3 HISHAM HASHEM matography (HPLC) method was developed and validated AYMAN A. GOUDA4 for simultaneous determination of xipamide (XIP), triam- terene (TRI) and hydrochlorothiazide (HCT) in their bulk 1 Faculty of Pharmacy powders and dosage forms. Chromatographic separation Pharmaceutical Chemistry Department was carried out in less than two minutes. The separation King Abdulaziz University was performed on a RP C-18 stationary phase with an iso- Saudi Arabia cratic elution system consisting of 0.03 mol L–1 orthophos- phoric acid (pH 2.3) and acetonitrile (ACN) as the mobile 2 Faculty of Pharmacy phase in the ratio of 50:50, at 2.0 mL min–1 fl ow rate at room Department of Analytical Chemistry temperature. Detection was performed at 220 nm. Valida- Zagazig University, Egypt tion was performed concerning system suitability, limits of detection and quantitation, accuracy, precision, linearity 3 Faculty of Pharmacy and robustness. Calibration curves were rectilinear over Pharmaceutical Chemistry Department the range of 0.195–100 μg mL–1 for all the drugs studied. Jazan University, Saudi Arabia Recovery values were 99.9, 99.6 and 99.0 % for XIP, TRI and HCT, respectively. The method was applied to simultane- 4 Faculty of Science ous determination of the studied analytes in their pharma- Department of Analytical Chemistry ceutical dosage forms.
    [Show full text]
  • Diuretics in the Treatment of Patients Who Present Congestive Heart Failure and Hypertension
    Journal of Human Hypertension (2002) 16 (Suppl 1), S104–S113 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh Diuretics in the treatment of patients who present congestive heart failure and hypertension AJ Reyes Institute of Cardiovascular Theory, Montevideo, Uruguay The main operational objective of diuretic therapy in ment natriuresis in patients with congestive heart failure patients who present congestive heart failure and hyper- and hypertension. The state of renal function, the exis- tension is to reduce or to suppress excess bodily fluid. tence of certain co-morbid conditions, potential Effective diuretic therapy decreases cardiac size when untoward drug actions, and possible interactions of the heart is dilated, and it reduces lung congestion and diuretics with nutrients and with other drugs are some excess water. Consequently, external respiratory work of the factors that must be considered at the time of diminishes and cardiac output would be redistributed in deciding on the diuretic drug(s) and dose(s) to be pre- favour of systemic vascular beds other than that of the scribed. Spironolactone has been found to increase life respiratory muscles; dyspnoea decreases markedly and expectancy and to reduce hospitalisation frequency there is a slight reduction in fatigue. This clinical when added to the conventional therapeutic regimen of improvement and the fall in body weight caused by patients with advanced congestive heart failure and sys- diuretics entail an increase in effort capacity. Sub- tolic dysfunction. Therefore, spironolactone should be sequent exercise training ameliorates the abnormal ven- the drug of choice to oppose the kaliuretic effect of a tilatory response to physical effort and the skeletal mus- loop or of a thiazide-type diuretic.
    [Show full text]
  • PRAC Recommendations on Signals Adopted at the 9-12 March 2020 PRAC Meeting
    6 April 20201 EMA/PRAC/111214/2020 Corr2,3,4 Pharmacovigilance Risk Assessment Committee (PRAC) PRAC recommendations on signals Adopted at the 9-12 March 2020 PRAC meeting This document provides an overview of the recommendations adopted by the Pharmacovigilance Risk Assessment Committee (PRAC) on the signals discussed during the meeting of 9-12 March 2020 (including the signal European Pharmacovigilance Issues Tracking Tool [EPITT]5 reference numbers). PRAC recommendations to provide supplementary information are directly actionable by the concerned marketing authorisation holders (MAHs). PRAC recommendations for regulatory action (e.g. amendment of the product information) are submitted to the Committee for Medicinal Products for Human Use (CHMP) for endorsement when the signal concerns Centrally Authorised Products (CAPs), and to the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) for information in the case of Nationally Authorised Products (NAPs). Thereafter, MAHs are expected to take action according to the PRAC recommendations. When appropriate, the PRAC may also recommend the conduct of additional analyses by the Agency or Member States. MAHs are reminded that in line with Article 16(3) of Regulation No (EU) 726/2004 and Article 23(3) of Directive 2001/83/EC, they shall ensure that their product information is kept up to date with the current scientific knowledge including the conclusions of the assessment and recommendations published on the European Medicines Agency (EMA) website (currently acting as the EU medicines webportal). For CAPs, at the time of publication, PRAC recommendations for update of product information have been agreed by the CHMP at their plenary meeting (23-26 March 2020) and corresponding variations will be assessed by the CHMP.
    [Show full text]